Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

JERSEY CITY, N.J., April 15, 2025--Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025. JERSEY CITY, N ...

Morgan Stanley lowered the firm’s price target on Organon (OGN) to $15 from $16 and keeps an Equal Weight rating on the shares. The firm ...

In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three ...